Preserving the Precious Gift of Sight

Humble Distinguished Directorship

Emmett A. Humble Distinguished Director

Looking at maturing retinal cells under microscope; photo by Andy Manis
Looking at maturing retinal cells under microscope; photo by Andy Manis

David M. Gamm, MD, PhD

Humble Distinguished Director, McPherson Eye Research Institute

Assistant Professor

Department of Ophthalmology and Visual Sciences

Waisman Center Stem Cell Research Program

University of Wisconsin School of Medicine and Public Health

Madison, WI

 

Dr. Gamm's Research Project

Modeling and Treating Retinal Disease with Human Induced Pluripotent Stem Cells (hiPSCs)
 

Current Research Interests

Dr. Gamm has pioneered the use of human induced pluripotent stem cell (hiPSC) technology to model human retinal diseases (including macular degenerations) in a laboratory dish – a powerful system to test drug and gene therapies. In addition, He is developing stem cell-based photoreceptor replacement approaches to treat retinal degenerative disease. His ultimate goal is to utilize the stem cell differentiation methods invented in his lab to produce clinical-grade cells for the treatment of blind and low vision patients. He is also studying the key biological steps through which photoreceptors are created from stem cells, so as to improve the efficiency of the process. Together with collaborators at the UW-Madison, Dr. Gamm’s team is paving the way for hiPSC therapies for retinal disease.

 

 

The above image shows human retinal pigment epithelium (outlined in red) derived from induced pluripotent stem cells created from a patient with Best Vitelliform Macular Dystrophy, a type of blinding disorder. The green areas are indicative of material that has not been properly digested by these cells, which is a prominent feature of this disease. (Image taken by Dr. Ruchira Singh, Gamm lab)
Print Friendly, PDF & Email


Change Font Size

Mission of RRF

The mission of the Retina Research Foundation is to reduce retinal blindness worldwide by funding programs in research and education. As a public charity, RRF raises funds from the private sector and the investment of its endowment funds.

RRF’s 48th Anniversary

October 1, 2017